Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-Positive Primary Breast Cancer”

67 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 67 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT01937117
What this trial is testing

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 88
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07417241
What this trial is testing

SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study

Who this might be right for
Breast CancerHER2-positive Breast Cancer
Peking University Cancer Hospital & Institute 100
Post-approval studies (Phase 4)Study completedNCT05631795
What this trial is testing

Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 40
Early research (Phase 1)WithdrawnNCT04498520
What this trial is testing

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8+32 more
Pamela Munster
Testing effectiveness (Phase 2)UnknownNCT05346107
What this trial is testing

PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer

Who this might be right for
Breast CancerHER2-positive Breast Cancer
Xijing Hospital 100
Testing effectiveness (Phase 2)Study completedNCT01172223
What this trial is testing

Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer

Who this might be right for
Breast Cancer
Prof Dirk Elling 81
Testing effectiveness (Phase 2)Study completedNCT03395899
What this trial is testing

Pre-operative Immunotherapy Combination Strategies in Breast Cancer

Who this might be right for
Breast CancerEstrogen Receptor-positive Breast Cancer
Queen Mary University of London 71
Large-scale testing (Phase 3)Study completedNCT01864746
What this trial is testing

Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery

Who this might be right for
Breast CancerHormonreceptor PositiveHer2-normal+2 more
GBG Forschungs GmbH 1,250
Testing effectiveness (Phase 2)Ended earlyNCT06844669
What this trial is testing

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Who this might be right for
HER2-positive Breast CancerHER2+ Breast Cancer
Washington University School of Medicine 7
Early research (Phase 1)Study completedNCT03236974
What this trial is testing

Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.

Who this might be right for
Postmenopausal Women With ER+ HER2- Primary Breast Cancer
AstraZeneca 49
Testing effectiveness (Phase 2)Ended earlyNCT01185509
What this trial is testing

Trastuzumab and Vinorelbine in Advanced Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast Cancer
Dana-Farber Cancer Institute 31
Testing effectiveness (Phase 2)Study completedNCT00717405
What this trial is testing

Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.

Who this might be right for
Breast Cancer
Hoffmann-La Roche 52
Large-scale testing (Phase 3)Active Not RecruitingNCT06126640
What this trial is testing

A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy

Who this might be right for
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Jiangsu HengRui Medicine Co., Ltd. 1,615
Testing effectiveness (Phase 2)Study completedNCT01816594
What this trial is testing

NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer

Who this might be right for
HER2-positive Newly Diagnosed, Primary Breast Cancer
Novartis Pharmaceuticals 50
Large-scale testing (Phase 3)Study completedNCT00288002
What this trial is testing

Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer

Who this might be right for
Breast Cancer
GBG Forschungs GmbH 1,500
Large-scale testing (Phase 3)Study completedNCT00553358
What this trial is testing

Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 455
Testing effectiveness (Phase 2)Study completedNCT02682693
What this trial is testing

Denosumab as an add-on Neoadjuvant Treatment (GeparX)

Who this might be right for
Breast Cancer Female NOSTubular Breast Cancer Stage IIMucinous Breast Cancer Stage II+4 more
GBG Forschungs GmbH 780
Large-scale testing (Phase 3)Active Not RecruitingNCT04622319
What this trial is testing

Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

Who this might be right for
HER2-Positive Primary Breast CancerResidual Invasive Breast Cancer
Daiichi Sankyo 1,600
Testing effectiveness (Phase 2)Ended earlyNCT01217411
What this trial is testing

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

Who this might be right for
Adult Solid NeoplasmExtensive Stage Lung Small Cell CarcinomaHER2/Neu Negative+10 more
National Cancer Institute (NCI) 5
Testing effectiveness (Phase 2)WithdrawnNCT00434031
What this trial is testing

CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer

Who this might be right for
Breast Cancer
National Cancer Institute, Naples
Next Page